APA (7th ed.) Citation

Furukawa, J., Kakei, Y., Murakami, S., Kita, H., Ueki, H., Hara, T., . . . Shirakawa, T. (2025). Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: A study protocol for a phase 1 multicenter, open-label, single-arm clinical trial. BMC cancer, 25(1), 195-11. https://doi.org/10.1186/s12885-025-13514-4

Chicago Style (17th ed.) Citation

Furukawa, Junya, et al. "Safety and Efficacy of Oral Cancer Vaccine B440 in Patients with PD-1/PD-L1 Inhibitor-resistant Advanced Urothelial Cancer: A Study Protocol for a Phase 1 Multicenter, Open-label, Single-arm Clinical Trial." BMC Cancer 25, no. 1 (2025): 195-11. https://doi.org/10.1186/s12885-025-13514-4.

MLA (9th ed.) Citation

Furukawa, Junya, et al. "Safety and Efficacy of Oral Cancer Vaccine B440 in Patients with PD-1/PD-L1 Inhibitor-resistant Advanced Urothelial Cancer: A Study Protocol for a Phase 1 Multicenter, Open-label, Single-arm Clinical Trial." BMC Cancer, vol. 25, no. 1, 2025, pp. 195-11, https://doi.org/10.1186/s12885-025-13514-4.